Trial intelligence / Profile preview

Genetic polymorphisms and response to ranibizumab vs bevacizumab in neovascular AMD

2024-518990-33-00Phase 4Authorised

Sponsor: Parc de Salut Mar
Start: Oct 2024
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 4, randomised, double-blind trial in exudative macular degeneration comparing Ranibizumab arm with Bevacizumab (Avastin) arm (2 arms). Primary endpoints: Change in visual acuity score at 1 year and Genetic polymorphism analysis. Planned start Oct 2024; status: authorised.

Drugs

ranibizumabbevacizumab

Conditions

exudative macular degeneration

Beyond the preview

Go deeper on 2024-518990-33-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-518990-33-00.